A Combination Therapy Comprising Varlitinib and an Anticancer Agent
Aslan Pharmaceuticals Pte Ltd.
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,357,494 | A Combination Therapy Comprising Varlitinib and an Anticancer Agent In force · High confidence UsedRemaining | Aslan Pharmaceuticals Pte Ltd. | In force | High confidence | ||
| US 10,849,899 | Combination Therapy Comprising Varlitinib and an Anticancer Agent Lapsed Dec 1, 2024 on the fee record High confidence | ASLAN Pharmaceuticals PTE LTD | Lapsed Dec 1, 2024 on the fee record | High confidence |
2 of 2 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Aslan Pharmaceuticals Pte Ltd..
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.